Work

Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps3163

Authors: John D. Powderly, Bartosz Chmielowski, Julie R. Brahmer, Sarina Anne Piha-Paul, Samantha Elizabeth Bowyer, Patricia LoRusso, Daniel V.T. Catenacci, Christina Wu, Minal A. Barve, Michael Jon Chisamore, Nicole Nasrah, Dan Johnson, William Ho

Institutions: Carolina BioOncology Institute, University of California, Los Angeles, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Linear Clinical Research, Yale University, University of Chicago Medical Center, Emory University, Mary Crowley Cancer Research Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Rapt Therapeutics (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2957328613

Cites:

Cited by: 6

Related to: 10